TY - JOUR
T1 - A clinical review of outcomes of the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (MTA)
AU - Murray, Desiree W.
AU - Arnold, L. Eugene
AU - Swanson, Jim
AU - Wells, Karen
AU - Burns, Karen
AU - Jensen, Peter
AU - Hechtman, Lily
AU - Paykina, Natalya
AU - Legato, Lauren
AU - Strauss, Tara
N1 - Funding Information:
Dr. Murray has received research support from Eli Lilly and Company, Addrenex Pharmaeuticals, and Athenagen. Dr. Arnold has received research support from Shire Pharmaceuticals, Eli Lilly and Company, Novartis Pharmaceuticals, Neuropharm Group, Noven, Targacept, and Sigma-Tau Pharmaceuticals; has served as a consultant for Shire Pharmaceuticals, Sigma-Tau Pharmaceuticals Neuropharm Group, Organon, and Novartis Pharmaceuticals; and has served on the speakers’ bureau for Ortho-McNeil Pharmaceutical, Shire Pharmaceuticals, and Novartis Pharmaceuticals. Dr. Swanson has received a research grant from McNeil; has served on advisory boards for UCB Pharma, Eli Lilly and Company, and Shire Pharmaceuticals; and has received honoraria from Ortho-McNeil Pharmaceutical and UCB Pharma. Dr. Jensen has served as a consultant for Best Practice, Inc., Shire Pharmaceuticals, Janssen-Ortho, and Ortho-McNeil Pharmaceutical and on the speakers’ bureau for Colorado Med Tech, CME Outfitters, Ortho-McNeil Pharmaceutical, and UCB Pharma. Dr. Hechtman has served on advisory boards and the speakers’ bureau and received research funds from Shire Pharmaceuticals, Janssen-Ortho, and Purdue Pharma. No other conflicts of interest relevant to this article were reported.
PY - 2008
Y1 - 2008
N2 - Over the past decade, the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder has provided a bewildering wealth of data (more than 70 peer-reviewed articles) addressing treatment-related questions for children with attention-deficit/ hyperactivity disorder. However, the take-home messages for clinicians may not always be clear. Therefore, this article reviews key findings, including relative benefits of medication and behavioral treatments, longterm effects at 2 and 3 years, treatment mediators and moderators, preliminary delinquency and substance use outcomes, and growth suppression related to stimulant use. Appropriate interpretations of the findings and their limitations are discussed, and recommendations for clinical practice are derived.
AB - Over the past decade, the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder has provided a bewildering wealth of data (more than 70 peer-reviewed articles) addressing treatment-related questions for children with attention-deficit/ hyperactivity disorder. However, the take-home messages for clinicians may not always be clear. Therefore, this article reviews key findings, including relative benefits of medication and behavioral treatments, longterm effects at 2 and 3 years, treatment mediators and moderators, preliminary delinquency and substance use outcomes, and growth suppression related to stimulant use. Appropriate interpretations of the findings and their limitations are discussed, and recommendations for clinical practice are derived.
UR - http://www.scopus.com/inward/record.url?scp=58649105068&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58649105068&partnerID=8YFLogxK
U2 - 10.1007/s11920-008-0068-4
DO - 10.1007/s11920-008-0068-4
M3 - Review article
C2 - 18803917
AN - SCOPUS:58649105068
SN - 1523-3812
VL - 10
SP - 424
EP - 431
JO - Current psychiatry reports
JF - Current psychiatry reports
IS - 5
ER -